A combination of chemotherapy and immunotherapy improves outcomes in colorectal cancer, suggesting a new treatment approach.
Compared with atezolizumab monotherapy, a combination of chemotherapy, atezolizumab, and bevacizumab led to dramatically improved progression-free survival in patients with mismatch repair-deficient /microsatellite instability–high metastatic colorectal cancer. Because these patients often experience disease progression on immunotherapy, the results suggest that the combination approach could improve how they fare.
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: